Cisplatin, gemcitabine, vinorelbine (PGV) vs cisplatin and gemcitabine (PG) vs cisplatin, gemcitabine, paclitaxel (PGT) in advanced NSCLC:: Final analysis a phase III trial

被引：0
|
作者：
Comella, G [1 ]
Frasci, G [1 ]
Panza, N [1 ]
Nicolella, G [1 ]
Manzione, I [1 ]
De Cataldis, G [1 ]
Cioffi, R [1 ]
Micillo, E [1 ]
Lorusso, V [1 ]
Bilancia, D [1 ]
Maiorino, L [1 ]
Piantedosi, FV [1 ]
Mangiameli, A [1 ]
Gravina, A [1 ]
Lamberti, A [1 ]
De Lena, M [1 ]
Comella, P [1 ]
机构：
[1] Tumor Inst Naples, So Italy Cooperat Oncol Grp, Naples, Italy
来源：
ANNALS OF ONCOLOGY | 2000年 / 11卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A10
引用
收藏
页码：3 / 3
页数：1
相关论文
共 50 条
  • [1] Cisplatin-gemcitabine-vinorelbine (PGV) vs cisplatin-vinorelbine (PV) vs cisplatin-gemcitabine (PG) in advanced non-small cell lung cancer (NSCLC). Interim analysis of a SICOG phase III trial
    Comella, P
    Panza, N
    Nicolella, GP
    Manzione, L
    Lorusso, V
    Cioffi, R
    Decataldis, G
    Maiorino, L
    Bilancia, D
    Comella, G
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S247 - S247
  • [2] Randomized phase II study of cisplatin/vinorelbine vs cisplatin/gemcitabine vs vinorelbine/gemcitabine in patients with advanced non-small cell lung cancer
    Tsai, CM
    Perng, RP
    Wang, GS
    Chen, YM
    INTERNATIONAL JOURNAL OF CANCER, 2002, : 78 - 78
  • [3] Cisplatin-gemcitabine vs. cisplatin-gemcitabine-vinorelbine vs. cisplatin-gemcitabine in advanced non-small-cell lung cancer. Final analysis of a Southern Italy Cooperative Oncology Group (SICOG) phase III trial.
    Comella, G
    Frasci, G
    Panza, N
    Nicolella, G
    Manzione, L
    De Cataldis, G
    Cioffi, R
    Micillo, E
    Lorusso, V
    Bilancia, D
    Maiorino, L
    Piantedosi, FV
    Mangiameli, A
    Gravina, A
    Lamberti, A
    De Lena, M
    Comella, P
    ANNALS OF ONCOLOGY, 2000, 11 : 107 - 107
  • [4] A Randomized Study Comparing Cisplatin/Paclitaxel Liposome vs Cisplatin/Gemcitabine in Chemonaive, Advanced Squamous NSCLC
    Zhou, C.
    Jiang, L.
    Dong, X.
    Gu, K.
    Pan, Y.
    Shi, Q.
    Zhang, G.
    Wang, H.
    Zhang, X.
    Yang, N.
    Li, Y.
    Xiong, J.
    Yi, T.
    Peng, M.
    Song, Y.
    Fan, Y.
    Cui, J.
    Chen, G.
    Tan, W.
    Zang, A.
    Guo, Q.
    Zhao, G.
    Wang, Z.
    He, J.
    Yao, W.
    Wu, X.
    Chen, K.
    Hu, X.
    Hu, C.
    Yue, L.
    Jiang, D.
    Wang, G.
    Liu, J.
    Yu, G.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S129 - S130
  • [5] Gemcitabine/vinorelbine followed by paclitaxel versus cisplatin/gemcitabine/vinorelbine versus cisplatin/paclitaxel in advanced non-small cell lung cancer: final results of the AASLC-AIO-3 phase III trial
    Pirker, Robert
    Fischer, Berthold
    Eberhardt, Wilfried
    Niederle, Norbert
    Mohn-Staudner, Andrea
    Ewert, Ralf
    Benisch, Peter
    Pfeifer, Wolfgang
    Gauler, Thomas
    Griesinger, Frank
    Minar, Wilma
    Buhl, Roland
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S286 - S286
  • [6] RESULTS OF A RANDOMIZED PHASE 2 TRIAL OF GEMCITABINE/CISPLATIN/INIPARIB (GCI) VS GEMCITABINE/CISPLATIN (GC) IN PATIENTS WITH STAGE IV NSCLC
    Besse, Benjamin
    Felip, Enriqueta
    Barlesi, Fabrice
    Mazieres, Julien
    Zalcman, Gerard
    Von Pawel, Joachim
    Reck, Martin
    Cappuzzo, Federico
    Ferry, David
    Carcereny, Enric
    Santoro, Armando
    Eberhardt, Wilfried
    Hughes, Andrew
    Lavialle, Sebastien
    Mery-mignard, Dominique
    Novello, Silvia
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S469 - S470
  • [7] Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer
    Stemmler, H. J.
    diGioia, D.
    Freier, W.
    Tessen, H. W.
    Gitsch, G.
    Jonat, W.
    Brugger, W.
    Kettner, E.
    Abenhardt, W.
    Tesch, H.
    Hurtz, H. J.
    Roesel, S.
    Brudler, O.
    Heinemann, V.
    BRITISH JOURNAL OF CANCER, 2011, 104 (07) : 1071 - 1078
  • [8] Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer
    H J Stemmler
    D diGioia
    W Freier
    H W Tessen
    G Gitsch
    W Jonat
    W Brugger
    E Kettner
    W Abenhardt
    H Tesch
    H J Hurtz
    S Rösel
    O Brudler
    V Heinemann
    British Journal of Cancer, 2011, 104 : 1071 - 1078
  • [9] Randomized trial comparing cisplatin, gemcitabine, and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small-cell lung cancer: Interim analysis of a phase III trial of the southern Italy Cooperative Oncology Group
    Comella, P
    Frasci, G
    Panza, N
    Manzione, L
    De Cataldis, G
    Cioffi, R
    Maiorino, L
    Micillo, E
    Lorusso, V
    Di Rienzo, G
    Filippelli, G
    Lamberti, A
    Natale, M
    Bilancia, D
    Nicolella, G
    Di Nota, A
    Comella, G
    JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (07) : 1451 - 1457
  • [10] Phase III study of Lipoplatin plus Gemcitabine versus Cisplatin plus Gemcitabine in advanced NSCLC; interim analysis
    Kosmas, C.
    Angel, J.
    Athanasiou, A.
    Rapti, A.
    Karanikas, C.
    Lambaki, S.
    Politis, N.
    Mylonakis, N.
    EJC SUPPLEMENTS, 2009, 7 (02): : 531 - 531
12345